Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone

Neuropsychopharmacology. 2009 Feb;34(3):775-85. doi: 10.1038/npp.2008.142. Epub 2008 Sep 17.


Stress and anxiety are mainly regulated by amygdala and hypothalamic circuitries involving several neurotransmitter systems and providing physiological responses to peripheral organs via the hypothalamic-pituitary-adrenal axis and other pathways. The role of endogenous opioid peptides in this process is largely unknown. Here we show for the first time that anxiolytic parameters of explorative behavior in mice lacking prodynorphin were increased 2-4-fold in the open field, the elevated plus maze and the light-dark test. Consistent with this, treatment of wild-type mice with selective kappa-opioid receptor antagonists GNTI or norbinaltorphimine showed the same effects. Furthermore, treatment of prodynorphin knockout animals with U-50488H, a selective kappa-opioid receptor agonist, fully reversed their anxiolytic phenotype. These behavioral data are supported by an approximal 30% reduction in corticotropin-releasing hormone (CRH) mRNA expression in the hypothalamic paraventricular nucleus and central amygdala and an accompanying 30-40% decrease in corticosterone serum levels in prodynorphin knockout mice. Although stress-induced increases in corticosterone levels were attenuated in prodynorphin knockout mice, they were associated with minor increases in depression-like behavior in the tail suspension and forced swim tests. Taken together, our data suggest a pronounced impact of endogenous prodynorphin-derived peptides on anxiety, but not stress coping ability and that these effects are mediated via kappa-opioid receptors. The delay in the behavioral response to kappa-opioid receptor agonists and antagonist treatment suggests an indirect control level for the action of dynorphin, probably by modulating the expression of CRH or neuropeptide Y, and subsequently influencing behavior.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / pharmacology
  • Amygdala / metabolism
  • Animals
  • Anxiety / metabolism*
  • Anxiety / physiopathology
  • Brain Stem / metabolism
  • Corticosterone* / blood
  • Corticotropin-Releasing Hormone / metabolism
  • Dynorphins / physiology
  • Enkephalins / genetics
  • Enkephalins / metabolism
  • Enkephalins / physiology*
  • Exploratory Behavior
  • Female
  • Guanidines
  • Hypothalamus / metabolism
  • Male
  • Maze Learning
  • Mesencephalon / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout / metabolism
  • Morphinans
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Neuropeptide Y / genetics
  • Neuropeptide Y / metabolism
  • Neuropeptide Y / physiology
  • Neuropeptides / genetics
  • Neuropeptides / metabolism*
  • Protein Precursors / genetics
  • Protein Precursors / metabolism
  • Protein Precursors / physiology*
  • Raphe Nuclei / metabolism
  • Receptors, Opioid, kappa* / agonists
  • Receptors, Opioid, kappa* / antagonists & inhibitors
  • Stress, Psychological / physiopathology


  • 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan
  • Enkephalins
  • Guanidines
  • Morphinans
  • Neuropeptide Y
  • Neuropeptides
  • Protein Precursors
  • Receptors, Opioid, kappa
  • norbinaltorphimine
  • Naltrexone
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Dynorphins
  • Corticotropin-Releasing Hormone
  • preproenkephalin
  • Corticosterone